Car-mscs

1. Car-mscs decrease graft-versus-host disease.

   “Preclinical studies have shown their effectiveness against glioblastoma, Ewing sarcoma, acute myeloid leukemia, and lung cancer, as well as graft-versus-host disease”

   Reviewpreclinical studies

   Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution

   Journal of hematology & oncology·27 Oct 2025

More on Graft-versus-host disease